Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 17Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Mantle-Cell 11Lymphoma 9Recurrence 5Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, Follicular 5Multiple Myeloma 2Lymphoproliferative Disorders 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Lymphatic Diseases 2Lung Neoplasms 2Leukemia 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Neoplasms 2Graft vs Host Disease 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bronchiolitis Obliterans Syndrome 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neurologic Manifestations 1Metastatic Pancreatic Adenocarcinoma 1Leukemia, Lymphoid 1Leukemia, B-Cell 1

Interventions

fludarabine phosphate 3Cyclophosphamide 3pegylated granulocyte colony-stimulating factor 1ibrutinib 1forodesine 1fludarabine 1blinatumomab 1Whole-Body Irradiation 1Tacrolimus 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Mesna 1Leukapheresis 1Immunotherapy, Adoptive 1Everolimus 1Bone Marrow Transplantation 1Biopsy 1Alemtuzumab 1ARQ531 12-(2-oxo-2-((3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy)aminoethyl)phosphonic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester sodium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Lymphoid × ibrutinib × Clear all
NCT01105247 2014-03-31

Safety of PCI-32765 in Chronic Lymphocytic Leukemia

Pharmacyclics LLC.

Phase 1/2 Completed
133 enrolled 10 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡